GSK's New Hepatitis B Drug Cure Rate Data to Be Released, Peak Sales Target Achievable

Overview

This report focuses on the detailed Phase III clinical data of GSK's chronic hepatitis B drug bepirovirsen, to be presented at the European Association for the Study of the Liver (EASL). Goldman Sachs believes that while the 15%-20% functional cure rate is below the 30% suggested by some cost-effectiveness analyses, as the first potential cure, it is sufficient to support regulatory approval and physician adoption. Commercial opportunity remains the key subsequent debate, with the company's guidance of over £2 billion peak sales deemed achievable, potentially reaching £3 billion if pricing or China market share exceeds expectations.

Core views

In terms of clinical value, bepirovirsen is a triple-action mechanism antisense oligonucleotide drug aimed at achieving functional cure (undetectable viral DNA and surface antigen 24 weeks post-treatment discontinuation). The Phase III B-WELL program met its primary endpoint in January 2026, with EASL data focusing on the magnitude of cure rates. Goldman Sachs' key opinion leader surveys suggest that in the absence of current cure options, a 15%-20% cure rate already holds clinical significance, particularly in the patient subgroup with baseline surface antigen ≤1000 IU/mL (Phase II data showed a 16% cure rate). Regarding commercial potential, there are over 250 million chronic hepatitis B patients globally, but diagnosis rates are below 10%. Goldman Sachs estimates peak sales of approximately £2.075 billion based on 35% penetration assumptions in the US, EU, and Japan, and 12.5% in China. Pricing strategy references hepatitis C cure drugs, with a total US cost assumption of $21,000 (net price $14,700) and China's net price at 15% of the US. The exclusive collaboration with Simcere Pharmaceutical covers over 5,000 medical centers, expected to enhance China market penetration. Valuation impact-wise, the current probability of success (PoS) assumption is 75%. If PoS is raised to 100% post clinical data release, the DCF-implied target price has a 2% upside. The target price of 1870p is derived from a 50% weighting each of DCF (1740p) and PE valuation (2000p).

Analysis framework

Goldman Sachs employs a dual-track valuation approach: DCF analysis assumes an 8.0% WACC and 0% perpetual growth rate, yielding 1740p/share; PE valuation is based on 10.5x 2027 expected EPS, yielding 2000p/share. Commercial forecasts reference hepatitis C cure drug pricing analogs (e.g., Mavyret, Epclusa) and incorporate cost-effectiveness threshold analyses (e.g., a $11,900 cost-saving threshold in the US at a 30% cure rate). Penetration assumptions account for regional differences, with conservative assumptions for China due to low diagnosis rates and market access restrictions.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  DCF Valuation Model

  Predicts future drug cash flows discounted to present value, adjusted for risk via probability of success. This report raises PoS from 75% to 100%, directly increasing valuation by 2%.

• Valuation MethodPE/PEG valuation

  Price-to-Earnings Valuation

  Based on 2027 expected EPS, applying a 10.5x PE multiple, reflecting market valuation multiples for pharmaceutical profitability.

• Industry Analysis FrameworkSupply-demand framework

  Unmet Medical Need Analysis

  Existing chronic hepatitis B therapies have below 5% cure rates; bepirovirsen as the first potential cure fills a market gap, supporting pricing power.

• Event Game Theory & Behavioral FinanceExpectation Gap/Management

  Clinical Data Expectation Management

  Market focus on whether cure rates meet the clinically relevant 15% threshold; exceeding expectations may drive stock re-rating.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• GSK PLC (GSK.L)

  Direct beneficiary, bepirovirsen is its core pipeline drug

  Strengths

  First potential chronic hepatitis B cure, US and China account for two-thirds of global opportunity

  Weaknesses

  Cure rate below some cost-effectiveness analysis suggested 30%, potential pricing pressure

  Comparison

  Compared to existing nucleoside analog therapies (<5% cure rate), bepirovirsen offers significant clinical advantage

  Risks

  Clinical data underperformance, competitive therapy progress, pricing pressure, slow China market penetration

Key data

• Functional Cure Rate Expectation15%-20%Phase III B-WELL program expected range, with better efficacy in baseline surface antigen ≤1000 IU/mL patient subgroup
• Peak Sales Target>£2 billionCompany guidance, Goldman Sachs base forecast £2.075 billion (2037), optimistic scenario up to £3 billion
• US Pricing Assumption$21,000 per treatment courseTotal cost, net price $14,700 (after 30% discount)
• China Pricing Assumption15% of US net priceApproximately $2,205 per treatment course, reflecting market differences
• Probability of Success (PoS)75%→100%Raised post clinical data release, target price implies 2% upside
• China Market Penetration Rate12.5%Conservative assumption, Simcere collaboration covers over 5,000 medical centers

Impact & implications

For GSK, successful bepirovirsen launch would mark the first chronic hepatitis B cure, significantly enhancing its infectious disease pipeline value. Goldman Sachs sees the over £2 billion sales target as achievable but highlights pricing pressure and China market penetration progress. Valuation-wise, raising PoS to 100% only adds 2% to the target price, reflecting current stock price already partially pricing in drug success. Long-term, if the drug proves to reduce cirrhosis risk, it could further expand market potential.

Risks

• Clinical data details underperform (e.g., cure rate below 15%)
• Regulatory approval delays or failures
• Pricing below assumptions (especially in the US)
• Slow China market penetration growth
• Competition from existing antivirals and generics
• Drug safety concerns (e.g., injection site reactions, ALT elevation)

What to watch

• Detailed cure rate data at EASL (May 28, 2026)
• US FDA approval decision (PDUFA date October 26, 2026)
• China NMPA approval progress and Simcere collaboration execution
• Drug pricing negotiation outcomes (especially US payer coverage)
• Subgroup analysis of baseline surface antigen impact on cure rates